Format

Send to

Choose Destination
Biologics. 2010 Feb 4;4:19-31.

Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib.

Author information

1
Visiting Fellow, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston, MA, USA;

Abstract

In the last decade a tremendous amount has been learned about the biology and treatment of gastrointestinal stromal tumor (GIST). Imatinib mesylate has revolutionized the treatment of metastatic GIST. In addition, the role of imatinib in localized GIST has gained much interest and may improve patient outcomes. Additionally, research efforts aimed at understanding the biology and the molecular heterogeneity of GIST both at initial presentation and at the time of resistance to imatinib, has helped guide rational approaches to treatment as well as future efforts aimed at treating imatinib-resistant GIST.

KEYWORDS:

GIST; TKI; gastrointestinal stromal tumors; imatinib; review; tyrosine kinase inhibitor

PMID:
20161982
PMCID:
PMC2819895

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center